Molecular Characterization of Residual Bladder Cancer after Neoadjuvant Pembrolizumab – Beyond the Abstract

transurethral resection of bladder tumour (TURBT) followed by neoadjuvant chemotherapy, standard-of-care therapy for muscle-invasive bladder cancer, neoadjuvant atezolizumab, Molecular subtypes of tumors collected at radical cystectomy.

Read the full article here

Related Articles